Aduro Biotech Europe
Aduro is developing novel therapies that induce highly targeted, potent and sustained immune responses against a variety of cancers. We have three diverse immunotherapy platforms – LADD (live, attenuated, double-deleted Listeria mononcytogenes), CDNs (cyclic dinucleotides) and B-select antibodies (B-select) that we believe are key to our fulfillment of our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.